Welcome to our dedicated page for Elite Hlth Sys SEC filings (Ticker: EHSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elite Health Systems Inc. filings document the regulatory record for a Delaware operating company, including proxy materials, 8-K material-event reports and late-filing notices. The company’s disclosures cover board elections, common-stock authorization, equity incentive plan approvals, share issuance for an acquisition and annual-report timing under Form 12b-25.
The filing record also identifies the company’s former name, U.S. Neurosurgical Holdings, Inc., and provides governance and capital-structure information tied to stockholder voting matters and public-company reporting obligations.
Elite Health Systems Inc. (EHSI) reported a wider quarterly loss as it builds its Medicare Advantage platform. For Q3 2025, the company recorded no revenue and a net loss of $1,161,000 versus $290,000 a year ago, driven by higher selling, general and administrative expenses of $1,165,000 (up from $387,000).
Cash and cash equivalents were $3,970,000, total stockholders’ equity was $5,020,000, and 21,939,924 common shares were outstanding as of October 31, 2025. Year‑to‑date, the net loss was $2,026,000 versus $1,034,000 in 2024. The company raised $5,825,000 earlier in 2025 and an additional $1,890,000 by September 30, 2025 at $0.95 per share, exceeding $3,000,000 by the filing date.
Elite Health received a Knox‑Keene license in May 2025 and CMS conditional approval in June 2025, began marketing in October 2025, and plans to begin providing services on January 1, 2026. Stockholders approved issuing 3,158,000 shares to acquire Physician Support Systems, Inc., which closed November 1, 2025. The filing notes substantial doubt about going concern at September 30, 2025, though management cites recent financings and plans to continue operations.
Elite Health Systems Inc. reported the results of a Special Meeting of Stockholders held on September 26, 2025. A total of 21,939,924 common shares were eligible to vote, and 14,688,791 votes were cast, establishing a quorum.
Stockholders voted on director nominees and additional proposals. Director vote totals disclosed include: Dr. Prasad Jeereddi with 14,632,106 votes for and 56,685 against; Alan Gold with 14,633,106 for and 55,685 against; William Leimkuhler with 14,633,106 for and 55,685 against; William St. Lawrence with 14,633,106 for and 55,685 against; and Dr. Haranath Policherla with 14,688,791 for, 0 against, and 0 abstentions.
The filing also lists proposal vote counts as follows: 14,487,901 for and 200,890 against; 14,497,016 for and 191,775 against; 14,031,106 for, 157,685 against, and 500,000 abstentions; 14,688,791 for, 0 against, and 0 abstentions; and 14,622,906 for and 65,885 against.
Elite Health Systems Inc. discloses an acquisition agreement involving its Chief Executive Officer, Dr. Prasad Anjaneya Jeereddi, and his daughter, Dr. Praveena Jeereddi, identified as the selling stockholders. The filing states Dr. Jeereddi served as a principal executive officer from July 2024 through the end of that year and that PEO compensation reflects the amounts shown in the Summary Compensation Table for Alan Gold and Dr. Jeereddi. The proxy references an Annex A that contains the Acquisition Agreement terms and urges readers to review that document in full because the summary may omit material contract details. The filing also lists plan governance topics such as eligibility and award limits, terms for options, SARs and stock awards, performance award agreements, change of control provisions, compliance with securities laws, and tax withholding.
Elite Health Systems Inc. entered into a Share Exchange Agreement to acquire 100% of Physician Support Systems, Inc. (“PSS”) from its stockholders. As consideration, Elite Health Systems will issue 3,158,000 shares of its common stock to the PSS selling stockholders.
The transaction involves related parties, as Chief Executive Officer Dr. Prasad Jeereddi owns 46% of PSS and his daughter, Dr. Praveena Jeereddi, owns 44%. The deal is not yet closed and is contingent on stockholder approval of the Exchange Agreement, an amendment to increase authorized common shares, and satisfaction of specified closing conditions and deliverables.